FDAsafety guidance66% confidence
FDA TA — ANDA219413
Source: FDA
Why This Matters
Why this matters: provides agency context on safety guidance that may shape timing or evidence expectations for Lupin Pharmaceuticals; the same agency is already in play for this signal, so precedent weight is higher.
Regulatory Analysis
Application ANDA219413. Sponsor: TEVA PHARMACEUTICALS, INC.. Submission status: TA. Submission type: ORIG. Review priority: STANDARD.
Supporting Context
- Therapeutic area
- Infectious Disease · Antibiotic
- Sub-indication
- General
Related signal: Lupin's Doxycycline ANDA204234 Receives AP Status from FDA